Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.

Breast cancer research and treatment - 1 Dec 2014

Pfeifer Werner, Sokolenko Anna P, Potapova Olga N, Bessonov Alexandr A, Ivantsov Alexandr O, Laptiev Sergey A, Zaitseva Olga A, Yatsuk Olga S, Matsko Dmitry E, Semiglazova Tatiana Yu, Togo Alexandr V, Imyanitov Evgeny N

Abstract excerpt

Breast carcinomas caused by inheritance of cancer-predisposing germ-line mutations have specific bioclinical features. This study aimed to analyze the efficacy of conventional cytotoxic treatment in BRCA1 and CHEK2 mutation carriers and non-carriers. The study included 415 Russian breast cancer patients aged 50 years or younger, who were subjected to various standard schemes of neoadjuvant therapy. The choice of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Checkpoint Kinase 2

Share to Germ-Line Mutation

Share to Heterozygote

Share to Neoadjuvant Therapy

Share to Taxoids

Source

Identifiers

PMID: 25414026
DOI: 10.1007/s10549-014-3206-1

Genes

BRCA1
CHEK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.PMID 25414026Read ↗

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.Semantic proximity Read ↗

Is the CHEK2 Gene Able to Offer Platinum Sensitivity Despite Low Variant Allele Frequency? A Case Report and Review in LiteratureSemantic proximity Read ↗

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read ↗

Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.Semantic proximity Read ↗

CHEK2 1100delC mutation is frequent among Russian breast cancer patients.Semantic proximity Read ↗

Mutational and Expressional Deregulation of the CHEK1 Gene in Breast Cancer Patients.Semantic proximity Read ↗

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patientsSemantic proximity Read ↗

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Semantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.Semantic proximity Read ↗

Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.Semantic proximity Read ↗

Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.